← Back to Search

Procedure

ExAblate Transcranial System for Brain Tumor

N/A
Waitlist Available
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Size of the targeted portion of the tumor (i.e. prescribed ROT) is less than 2.5 cm in diameter (8 cm3 in volume). The non-targeted tumor tissue may exceed the targeted volume.
OR Patients with metastatic brain cancer that has progressed despite prior radiotherapy and local therapy is requested by the oncologist. This treatment will be offered as an option for those patients where surgery is not indicated and discussed with the potential options for repeat radiotherapy or salvage radiosurgery by the multidisciplinary team.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of exablate procedure
Awards & highlights

Study Summary

This trial will test whether transcranial MRI-guided focused ultrasound surgery is safe and effective in treating brain tumors.

Eligible Conditions
  • Brain Tumor

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of exablate procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of exablate procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate Safety of ExAblate Transcranial Device

Trial Design

1Treatment groups
Experimental Treatment
Group I: ExAblate Transcranial DeviceExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ExAblate Transcranial System
2011
N/A
~30

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
88 Previous Clinical Trials
3,694 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025